Cited 0 times in

Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication

Authors
 Cheri L Deal  ;  Joel Steelman  ;  Elpis Vlachopapadopoulou  ;  Renata Stawerska  ;  Lawrence A Silverman  ;  Moshe Phillip  ;  Ho-Seong Kim  ;  CheolWoo Ko  ;  Oleg Malievskiy  ;  Jose F Cara  ;  Carl L Roland  ;  Carrie Turich Taylor  ;  Srinivas Rao Valluri  ;  Michael P Wajnrajch  ;  Aleksandra Pastrak  ;  Bradley S Miller 
Citation
 THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, Vol.15 : 20420188241277404, 2024-11 
Journal Title
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
ISSN
 2042-0188 
Issue Date
2024-11
Keywords
growth hormone ; growth hormone deficiency ; somatrogon ; somatropin
Abstract
The efficacy of weekly somatrogon injections was no different from that of daily somatropin injections to treat children who don't make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial. ○ Children treated with weekly somatrogon had an increased growth rate, similar to that of children treated with daily somatropin. • The safety of weekly somatrogon injections was similar to that of daily somatropin injections. The original scientific article on which this summary is based was published in The Journal of Clinical Endocrinology & Metabolism and can be accessed for free at: https://academic.oup.com/jcem/article/107/7/e2717/6566444. The details of the original article are as follows: Cheri L. Deal, Joel Steelman, Elpis Vlachopapadopoulou, Renata Stawerska, Lawrence A Silverman, Moshe Phillip, Ho-Seong Kim, CheolWoo Ko, Oleg Malievskiy, Jose F. Cara, Carl L. Roland, Carrie Turich Taylor, Srinivas Rao Valluri, Michael P. Wajnrajch, Aleksandra Pastrak, and Bradley S. Miller. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 2022; 107(7): e2717-e2728. The purpose of this plain language summary is to help you to understand the findings from recent research. • Somatrogon is used to treat growth hormone deficiency (the condition under study that is discussed in this summary). Approval varies by country; please check with your local healthcare provider for more details. • The results of this study may differ from those of other studies. Physicians/providers should make treatment decisions based on all available evidence and not on the results of a single study.
Files in This Item:
T992024840.pdf Download
DOI
10.1177/20420188241277404
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Ho Seong(김호성) ORCID logo https://orcid.org/0000-0003-1135-099X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/202400
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links